With 2020 as one of the most important times in health journalism history, the Awards for Excellence in Health Care Journalism is ready to accept entries to recognize the best health reporting in print, broadcast and online media.
First-place winners earn $500 and a framed certificate. They also receive complimentary lodging for two nights and registration for the annual conference, June 24-27, in Austin. Winners are recognized at the annual awards luncheon. Continue reading
As various COVID-19 vaccine candidates make their way through clinical trials — see this nice update on where things stand from Helen Branswell at STAT — journalists need to be scrutinizing the findings as closely as possible when reporting on them. But what do you look for?
The questions I include from this piece from Elemental, primarily aimed at laypersons, are a good starting point. Then, getting more detailed, look to this brief thread of tweets from Vinay Prasad, M.D., a hematologist-oncologist and associate professor of medicine at the University of California, San Francisco. Continue reading
Please welcome these new professional and student members to AHCJ.
All new members are welcome to stop by this post’s comment section to introduce themselves. Continue reading
Until 2020, many Americans (except health reporters) tended to consider influenza as just a nuisance winter illness that might keep one in bed for a few days. However, this year, with COVID-19 still roiling the country, the flu needs to be considered more seriously.
Adding to concerns are polls showing that people may be reluctant to get a flu shot, which may influence others to hold off. CNN reports that one in three parents said they had no plan to go to their doctor’s office and vaccinate their kids, even though more than 100 children die of the flu each year. Most of the children that die from the flu didn’t get a flu shot. Continue reading
A recent Pew Research poll found that the proportion of Americans who said they would get a COVID-19 vaccine when it is released has dropped sharply since May. This isn’t necessarily very surprising, given the federal administration’s shenanigans with the CDC, documented in excellent reporting at Politico by Dan Diamond and the NYT by Apoorva Mandavilli. Then there’s the experience at the FDA, where emergency use authorizations were used for hydroxychloroquine and convalescent plasma before adequate evidence to support either one was available. Continue reading
Approximately 80% of COVID-19 related deaths in the United States have been among people 65 or older, according to the Centers for Disease Control and Prevention. But a research letter published online in JAMA Internal Medicine on Sept. 28 reported that more than half of COVID-19 clinical trials were “at high risk for excluding older adults,” and none included seniors as part of vaccine trials early in the pandemic.
Despite a National Institute of Health policy mandating the inclusion of older adults in appropriate clinical trials, older adults were left out more often than not as scientists struggled to get a handle on the coronavirus. Researchers found that 53% of trials they reviewed did not include those older than 65 for a variety of reasons, including compliance concerns, co-morbid conditions or technology requirements. About one in four of the trials reviewed by the researchers included an age “cutoff” that would exclude adults age 65 to 80, as UPI reported. Continue reading